Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Mexico.
The approval in Mexico follows approvals of Vyzulta in the United States and Canada. Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
“Vyzulta is now approved in three major markets. This approval will contribute to Nicox revenue stream and it validates that Nicox is continuing to maximize the value from our partnered assets to complement our own development activities, further reinforced by our recent Zerviate license in South Korea and the forthcoming commercial launch of Zerviate in the U.S. by our partner Eyevance,” Gavin Spencer, Chief Business Officer of Nicox, said in a company news release.
Nicox receives increasing tiered net royalties of 6% to 12% on global sales of Vyzulta as well as up to $150 million in potential future milestones.